Associations - Erbitux (cetuximab)

BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	cetuximab + trametinib + dabrafenib Sensitive: A2 - Guideline ASCO-GI 2023 - 2 weeks (New C3) cetuximab + trametinib + dabrafenib Sensitive : A2 ASCO-GI 2023 - 2wk	cetuximab + trametinib + dabrafenib Sensitive: A2 - Guideline ASCO-GI 2023 - 2 weeks cetuximab + trametinib + dabrafenib Sensitive : A2 ASCO-GI 2023 - 2 weeks - (New C3)
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	cetuximab + encorafenib Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks (New C3) cetuximab + encorafenib Sensitive : A1 ASCO-GI 2023 - 2wk	cetuximab + encorafenib Sensitive: A1 - Approval ASCO-GI 2023 - 2 weeks cetuximab + encorafenib Sensitive : A1 ASCO-GI 2023 - 2 weeks - (New C3)
KRAS wild-type	Colorectal Cancer	KRAS wild-type	Colorectal Cancer	cetuximab Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks (New C3) cetuximab Sensitive : C2 ASCO-GI 2023 - 2wk	cetuximab Sensitive: C2 – Inclusion Criteria ASCO-GI 2023 - 2 weeks cetuximab Sensitive : C2 ASCO-GI 2023 - 2 weeks - (New C3)
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	cetuximab + tislelizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) cetuximab + tislelizumab Sensitive : C3 ASCO-GI 2023 - 2wk	cetuximab + tislelizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks cetuximab + tislelizumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
EREG overexpression + AREG overexpression	Colorectal Cancer	EREG overexpression + AREG overexpression	Colorectal Cancer	cetuximab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) cetuximab Sensitive : C3 ASCO-GI 2023 - 2wk	cetuximab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks cetuximab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	cetuximab + encorafenib + binimetinib Sensitive: A1 - Approval cetuximab + encorafenib + binimetinib Sensitive : A1	cetuximab + encorafenib + binimetinib Sensitive: A1 - Approval cetuximab + encorafenib + binimetinib Sensitive : A1
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	cetuximab Sensitive: A1 - Approval cetuximab Sensitive : A1	cetuximab Sensitive: A1 - Approval cetuximab Sensitive : A1
EGFR expression	Colorectal Cancer	EGFR expression	Colorectal Cancer	cetuximab Sensitive: A1 - Approval cetuximab Sensitive : A1	cetuximab Sensitive: A1 - Approval cetuximab Sensitive : A1
KRAS Q61	Colorectal Cancer	KRAS Q61	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
KRAS A146	Colorectal Cancer	KRAS A146	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
KRAS G13	Colorectal Cancer	KRAS G13	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
KRAS G12	Colorectal Cancer	KRAS G12	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
KRAS K117	Colorectal Cancer	KRAS K117	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
KRAS A59	Colorectal Cancer	KRAS A59	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
NRAS Q61	Colorectal Cancer	NRAS Q61	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
NRAS G13	Colorectal Cancer	NRAS G13	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
NRAS G12	Colorectal Cancer	NRAS G12	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
NRAS A146	Colorectal Cancer	NRAS A146	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
NRAS H117	Colorectal Cancer	NRAS H117	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
NRAS A59	Colorectal Cancer	NRAS A59	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
NRAS exon 4 mutation	Colorectal Cancer	NRAS exon 4 mutation	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2
No biomarker	Oral Cancer	No biomarker	Oral Cancer	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2
No biomarker	Oropharyngeal Cancer	No biomarker	Oropharyngeal Cancer	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2
NRAS mutation	Colorectal Cancer	NRAS mutation	Colorectal Cancer	cetuximab Resistant: A2 - Guideline cetuximab Resistant : A2	cetuximab Resistant: A2 - Guideline cetuximab Resistant : A2
No biomarker	Penile Cancer	No biomarker	Penile Cancer	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2
PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2
KRAS G13D	Colorectal Cancer	KRAS G13D	Colorectal Cancer	cetuximab Resistant: A2 - Guideline cetuximab Resistant : A2	cetuximab Resistant: A2 - Guideline cetuximab Resistant : A2
PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2
No biomarker	Nasopharyngeal Carcinoma	No biomarker	Nasopharyngeal Carcinoma	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2
NRAS exon 2 mutation	Colorectal Cancer	NRAS exon 2 mutation	Colorectal Cancer	cetuximab Resistant: A2 - Guideline cetuximab Resistant : A2	cetuximab Resistant: A2 - Guideline cetuximab Resistant : A2
NRAS exon 3 mutation	Colorectal Cancer	NRAS exon 3 mutation	Colorectal Cancer	cetuximab Resistant: A2 - Guideline cetuximab Resistant : A2	cetuximab Resistant: A2 - Guideline cetuximab Resistant : A2
No biomarker	Colon Cancer	No biomarker	Colon Cancer	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2
BRAF V600	Rectal Cancer	BRAF V600	Rectal Cancer	cetuximab + encorafenib Sensitive: A2 - Guideline cetuximab + encorafenib Sensitive : A2	cetuximab + encorafenib Sensitive: A2 - Guideline cetuximab + encorafenib Sensitive : A2
No biomarker	Squamous Cell Skin Cancer	No biomarker	Squamous Cell Skin Cancer	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	cetuximab + BMS-582664 Resistant: A2 - Guideline cetuximab + BMS-582664 Resistant : A2	cetuximab + BMS-582664 Resistant: A2 - Guideline cetuximab + BMS-582664 Resistant : A2

Erbitux (cetuximab)

Associations
(316)

Associations
(316)

Erbitux (cetuximab)

Associations(316)

Associations(316)

Associations
(316)

Associations
(316)